You might have heard of them. Novo Nordisk is currently experiencing an unprecedented period of growth and global attention, almost entirely driven by the spectacular success of its GLP-1 receptor agonist drugs, Ozempic (for type 2 diabetes) and Wegovy (for weight management).

Nordisk stock is down due to its significantly reduced 2025 sales and profit outlook, citing weaker-than-expected demand for its key weight-loss drug Wegovy and diabetes drug Ozempic

It is currently very cheap. Investors are dumping it in panic.  A lot of emotion is in the stock at the moment.

The company has 10 to 15 percen earnings growth, super profitable, and a PE of 12 ish.

Despite lower guidance earnings are increasing and the PE ratio is very low. Again: unpopularity is opportunity. In the long term value of companies are driven by earnings.

Some positive signs are starting to accumulate, but still very cheap. I bought at the bottom more or less. A great addition to your portfolio and very uncorrelated with mining and China.